Neoadjuvant chemotherapy in stage III NSCLC

Jeffrey Allen, Mohammad Jahanzeb

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer-related mortality in the United States. Current standard care for treating NSCLC is surgical resection, when feasible, followed by adjuvant chemotherapy in stages II and III. Neoadjuvant or induction chemotherapy may have several potential advantages compared with adjuvant chemotherapy and has been evaluated in randomized and nonrandomized clinical trials in NSCLC. This article reviews the data for neoadjuvant chemotherapy in NSCLC with a particular focus on regionally advanced disease (stage III) that is still amenable to surgical resection.

Original languageEnglish (US)
Pages (from-to)285-293
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number3
StatePublished - 2008
Externally publishedYes


  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer
  • Review

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Neoadjuvant chemotherapy in stage III NSCLC'. Together they form a unique fingerprint.

Cite this